Commercial insight into the pharma and biotech sector.
WORLD PREVIEW 2016 - Beyond the patent cliff
The latest edition of EvaluatePharma®’s World Preview 2016, published June 2011, shows the rheumatoid arthritis treatment Humira will assume Lipitor’s crown as the world’s biggest selling drug, while Pfizer will cling on to its ranking as the biggest seller of prescription medicines through to 2016.
This new edition of World Preview 2016 once again brings together many of our analyses to provide a top level insight, from the world’s financial markets, into the expected performance of the industry between now and 2016. The report offers an updated analysis of the market focusing on the changes in 2016 forecasts since last year's World Preview 2016 published May 2010.
Download World Preview 2016 (June 2011)
Based on EvaluatePharma®’s coverage of the world’s leading 3,000 pharmaceutical and biotech companies, World Preview 2016 highlights trends in prescription drug sales, patent risk, R&D spend, global brand sales and market performance by therapy area, plus a brief review of 2010 performance.
New analysis this year from EvaluatePharma® Venture Financing and EventAnalyzer includes:
- Venture Financing Analysis: 2006 to 2010
- Key Product Events Positively Impacting Shareholder Value in 2010
- Key Product Events Negatively Impacting Shareholder Value in 2010
EvaluatePharma®’s World Preview 2016 Analysis Highlights:
- 2016 forecasts for the top 50 products have increased by $21.7bn (+13% upgrade) since April 2010
- Worldwide prescription drug sales total $853bn in 2016; Since April 2010 growth revised up from 2.9% to 4.0% (CAGR) over 2010 – 2016
- Over $255bn of sales at risk from patent expirations in 2011-16
- Humira world's largest selling product in 2016
- Pfizer, Novartis and Sanofi competing for top spot in 2016
- Biotech products fail to overtake small molecule sales within top 100 drugs by 2016
- Global pharmaceutical R&D spend returns to growth in 2010 following unprecedented decline in 2009; still over investment
- Pfizer’s 2016 R&D spend revised down by $1.2bn since April 2010
- Anti-coagulants set to record highest growth of major therapy categories to 2016
- Best year for NME approvals since 2004 as sales potential doubles; number of new drugs approved down 24%
- GSK falls out of top 5 in 2010; first time since late 1980s
- Teva continues to dominate generic drug market in 2010
- Roche’s company value slumps in 2010 due to setbacks to Avastin and taspoglutide
- Novo Nordisk’s share price soars in 2010 following series of positive events within anti-diabetic business